info@biomedres.us
+1 (502) 904-2126
One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA
Site Map
ISSN: 2574 -1241
ISSN: 2574 -1241
Received: April 15, 2018; Published: April 30, 2018
DOI: 10.26717/BJSTR.2018.04.001015
Monoclonal antibodies (mAbs) in oncology are usually administered in body-size-based or fixed dosing schedules. However, the minor effects of body size on distribution and elimination of mAbs, as well as a series of practical advantages could support their fixed dosing use.
Kewords: FDA: US Food and Drug Administration; EMA: European Medicines Agency; NSCLC: Non Small Cell Lung Cancer; RCC: Renal Cell Carcinoma; BC: Breast Cancer; UC: Urothelial Carcinoma; CHL: Classical Hodgkin’s Lymphoma; HNSCC: Head and Neck Squamous Cell Carcinoma; HCC: Hepatocellular Carcinoma; GC: Gastric Cancer; CLL: Cronic Lymphocytic Leukaemia; NHL: Non-Hodgkin’s Lymphoma; FL: Follicular Lymphoma; DLBCL: Diffuse Large B-Cell Lymphoma; ; MSI-H: High Microsatellite Instability; IV: Intravenous; SC: SubCutaneous Q2W: Every Two Weeks; Q4W: Every Four Weeks
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Department of Chemistry, Semenov Institute of Chemical Physics, USSR Academy of Sciences, Moscow, Russia
Pharmaco-kinetics, dynamics and Drug Metabolism, Touro College of Pharmacy, USA
Professor of Nuclear Medicine, Faculty of Medicine and Surgery, University of Milan, Milan, Italy
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China
Full Text
PDF
